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The clinical problem of tumour non-responsiveness is the
main factor limiting the success of anticancer chemotherapy,
with both inherent and acquired resistance playing a role.
The basis of acquired drug resistance has been extensively
studied in rodent and human cells in culture using single or
multistep selections, but often with drug concentrations in
excess of those achievable pharmacologically.
Many major mechanisms leading to drug resistant pheno-
types have been identified to date and some of these have
been entensively reviewed recently. They include:
(1) Deletion or point mutations in genes encoding target
enzymes, e.g., HPRT conferring resistance to 6-thioguanine
and 6-mercaptopurine (Brennand & Caskey, 1985).
(2) Amplification of genes e.g. DHFR conferring resis-
tance to methotrexate (Schimke et al., 1977; Schimke, 1984),
the multifunctional CAD gene conferring resistance to N-
(phosphonoacetyl)-L-aspartate (Wahl et al., 1979), MDR1
encoding the gpl70 glycoprotein conferring multiple drug
resistance (Moscow & Cowan, 1988; Pastan & Gottesman,
1988; Deuchars & Ling, 1989) and mutated HPRT and
APRT (Turner et al., 1985; Nalbantoglu & Meuth, 1986).
(3) Differences in repair capacity or in the distribution of
DNA repair (Fox & Roberts, 1987).
(4) Increased radical scavenging or increased rates of drug
detoxification e.g. by glutathione S transferases (Puchalski &
Fahl, 1990; Moscow et al., 1988).
(5) Alterations in sensitivity or levels of activity of topois-
omerase II in cells resistant to e.g. ellipticine derivatives or
amsacrine (Kohn et al., 1987; Li, 1987; Rose, 1988).
(6) Alterations in drug transport other than those mediat-
ed by the mdr proteins e.g. the carrier mediated transport of
melphalan (Goldenberg & Begleiter, 1984).
Resistance to cytotoxic drugs is generally accepted to be a
more common property of tumour cells than normal cells.
This belief stems from observations of cells in vitro which
show that tumour cells more readily amplify their target
genes than normal cells (Wright et al., 1990 and refs therein)
and from progression-linked changes in the pathways of
purine and pyrimidine biosynthesis (Weber, 1983). The
clinical experience is that in many cases more than one
mechanism may be operative and not all causes are identi-
fiable. In vivo non-responsiveness is also influenced by a
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phate; GTP, guanosine triphosphate; NBMPR, nitrobenzyl-thio-
inosine; TK, tymidine kinase; ADP, adenosine diphosphate; 5NT, 5'
nucleotidase; 6MP, 6 mercaptopurine; 6TG, 6-thioguanine; NP, nuc-
leoside phosphorylase; ADA, adenosine deaminase; AP, alkaline
phosphatase.
number offactors (reviewed by Whitehouse, 1985) not opera-
tive at the cellular level, for example access of the drug to the
tumour. In the present paper we review the evidence that
nucleoside and nucleobase salvage pathways are an impor-
tant and often overlooked means of circumventing drug
action.
Nucleotide salvage is a mechanismfor circumventing
antimetabolite action
The majority ofcurrently used anticancer drugs are cytotoxic
either by inhibiting DNA synthesis or by damaging the DNA
template by alkylation or intercalation. Thus their limited
selectivity will be significantly influenced by differences in
proliferation rates and nucleotide metabolism between the
tumour cells and normal tissues. Based on this premise, over
many years Weber and colleagues have investigated differ-
ences in nucleic acid metabolism between normal rat liver
and hepatoma cells. Their results suggested that the activities
ofkey enzymes controlling anabolic pathways were enhanced
whereas those controlling catabolic pathways were diminish-
ed in tumour cells. However, since the majority of their
experiments were done on whole tissue extracts it is difficult
to conclude whether the differences in levels of expression of
anabolic enzymes in tumour cells were related to differences
in proliferation rates. Subsequently these observations were
found to be relevant for human tumours including hepato-
carcinoma, renal cell carcinoma, lung neoplasia and leu-
kaemia (Weber, 1983) and formed a basis for a rational
approach to the selection of new drugs that would speci-
fically inhibit key enzymes whose activity is enhanced, e.g.
the use of tiazofurin to inhibit IMPD (Weber et al., 1988).
IMP is a key intermediate of purine nucleotide synthesis
(Figure 1) as are UMP and TMP in pyrimidine nucleotide
synthesis (Figure 2). These metabolites are synthesised by
both de novo and salvage pathways and are focal inter-
mediates in the interconversion of nucleotides. The relative
contributions of de novo and salvage pathways to the syn-
thesis of these intermediates varies between different tissues.
Human lymphocytes (Williams, 1962; Lajtha & Vane, 1958;
Scavannec et al., 1982), bone marrow cells and cells of
intestinal and colonic mucosa (Bronstein et al., 1983; Leleiko
et al., 1983; Mackinnon & Deller, 1973; Saviano & Clifford,
1981) rely very strongly on salvage synthesis and even in
leukaemic cells, where de novo synthesis is increased, there is
still a 20-fold excess of salvage activity over that of de novo
synthesis. Recent work from Weber's group (Natsumeda et
al., 1984, 1989) has shown that in many other normal tissues
and tumours the salvage flux is greater than that of de novo
synthesis and furthermore inhibition of de novo synthesis by
antitumour agents leads to even higher salvage activity (Nat-
sumeda et al., 1989). This observation has led to the hypo-
thesis that some forms of unresponsiveness to chemotherapy
by inhibitors of de novo synthesis may result, not from any
effect of the drug on its target enzyme, but by the circumven-
tion of inhibition via salvage uptake.
If the above hypothesis is correct, different tumours should
exhibit widely differing levels ofspecific enzyme activities that
may be unrelated to their population doubling time and
growth fraction. Wide variations in levels of expression of
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Figure 1 The enzymes catalysing the numbered reactions are as
follows:
1 Phosphoribosyl pyrophosphate EC 2.4.2.17
synthetase
2 Phosphoribosyl pyrophosphate amido EC 2.4.2.14
transferase
3 Phosphoribosyl glycinamide synthetase EC 6.3.4.13
4 Phosphoribosyl glycinamide formyl- EC 2.1.2.2
transferase
5 Phosphoribosyl formylglycinamide syn- EC 2.1.2.3
thetase
6 Phosphoribosyl aminoimidazole syn- EC 6.3.3.1
thetase
7 Phosphoribosyl aminoimidazole carbox- EC 4.1.1.21
ylase
8 Phosphoribosyl aminoimidazole succino- EC 6.3.2.6
carboxamide synthase
9 Adenylosuccinate lyase EC 4.3.2.2
10 Phosphoribosyl aminoimidazole carbox- EC 2.1.2.3
amide formyltransferase
11 IMP cyclohydrolase EC 3.5.4.10
12 5'Nucleotidase EC 3.1.3.5
13 Nucleoside kinase EC 2.7.4.3
14 Hypoxanthine phosphoribosyl trans- EC 2.4.2.8
ferase
15 Adenine phosphoribosyl transferase EC 2.4.2.7
16 Nucleoside phosphorylase EC 3.4.2.1
17 IMP dehydrogenase EC 1.2.1.14
18 AMP deaminase EC 3.5.4.17
19 adenylosuccinate synthetase EC 6.3.4.4
Abbreviations: R5P, a D-ribose-5-phosphate; PRPP, 5-phospho a
D-ribose I phosphoric acid; PRA, 5-phospho D-ribosylamine;
GAR, 5-phosphoribosyl glycinamide; FGAR, 5-phosphoribosyl
N-formylglycinamide; FGAM, 5-phosphoribosyl N-formylglycin-
amidine; AIR, 5-phosphoribosyl aminoimidazole; AICR, 5-phos-
phoribosyl 5 aminoimidazole 4-carboxylic acid; AICAR, 5-phos-
phoribosyl 4-(N-succinocarboxamide) 5-aminoimidazole; AICAR
5-phosphoribosyl 4-carboxamide 5-aminoimidazole; FAICR, 5-
phosphoribosyl 4-carboxamide-5-formaminoimidazole; IMP, Ino-
sinic acid; GMP, Guanylic acid; XMP, Xanthanylic acid; AMPS,
Adenylosuccinate; AMP, Adenylic acid, Guo, Guanosine; G,
Guanine; XO, Xanthosine; X, Xanthine; Ino, Inosine; Hx, Hypo-
xanthine; Ado, Adenosine; A, Adenine; R-1-P, Ribose-l-phos-
phate.
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Figure 2 The enzymes catalysing the numbered reactions are as
follows:
1 Carbamoyl phosphate synthase EC 2.1.3.2
2 Aspartate transcarbamylase EC 2.5.2.3
3 Dihydroorotase EC 6.3.4.16
4 Dihydroorotate dehydrogenase EC 1.3.3.1
5 Orotate phosphoribosyl transferase EC 2.4.2.10
6 Orotate monophosphate decarboxylase EC 4.1.1.23
7 Thymidine phosphorylase EC 2.4.2.4
8 Thymidine kinase EC 2.7.1.21
9 Thymidylate synthase EC 2.1.1.45
10 Uridine kinase EC 2.42.3
11 Uridine phosphorylase EC 2.4.2.3
12 Uridylate kinase EC 2.7.1.48
13 Ribonucleotide reductase EC 1.7.14.1
14 Nucleotidase EC 3.1.3.5
15 Dihydrouracil dehydrogenase EC 1.3.1.1
Abbreviations: C02, carbon dioxide; NH3, ammonia; ATP, ade-
nosine triphosphate; CP, carbamyl phosphate; C-L-A, Carbamyl
L-aspartate; 4.5DHO, L-dihydroorotic acid; OR, orotic acid;
OR5P, orotidine 5 phosphate; UMP, uridine 5 monophosphate;
UDP, uridine diphosphate; dUDP, deoxyuridine diphosphate;
dUMP, deoxyuridine monophosphate; UdR, uridine; U, Uracil;
dTMP, deoxythymidine monophosphate; TdR, thymidine; T, thy-
mine.
several enzymes of purine metabolism have been noted in
both normal and tumour tissue. HPRT activity was elevated
relative to normal tissue in the majority of tumour samples
(breast and intestine) with levels ranging 0.2-2.0Umg'1.
Nucleoside phosphorylase (NP) and ADA were also raised in
tumour tissue whereas AP and 5NT activities were unchang-
ed (Camici et al., 1990). Although no attempt was made to
correlate levels ofexpression with growth rate or proliferative
fraction, the range of values suggests that they may be
strongly influenced by some of the mechanisms discussed
below.
In studies in this laboratory, in which four different human
tumour lines (EJ bladder carcinoma, HOC8 ovarian carcin-
oma, MCF7 and HDA 231 breast carcinoma) were tested for
methotrexate resistance under identical conditions a spectrum
of resistance was observed which was unrelated to growth
rate and phenotype (Kinsella unpublished observations).
No detailed molecular mechanism has been proposed to
explain the altered balance of de novo and salvage synthesis
observed by Weber et al. One possibility, suggested by Dut-
rillaux and Mulerio (1986), relates to the chromosome
imbalance frequently observed in tumours. Using colorectal
carcinoma as an example they have documented specific
gains and losses involving a duplication of chromosome 17p
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which carries the thymidine kinase gene, a loss of chromo-
some 18 which carries the gene for thymidylate synthase and
deletions in chromosome 5 which carries the gene for DHFR.
Whilst such chromosome changes may make a contribution
to altering the balance of de novo and salvage nucleotide
synthesis, this is probably too simplistic an interpretation as
there may be many compensatory changes in gene expres-
sion. Presently available data (Table I) indicate that there are
genes coding for enzymes involved in nucleic acid metabolism
on most human chromosomes and in some cases genes
coding for enzymes catalysing successive steps are present in
the same region of the chromosome e.g. 21q22.1 (Table I).
This and other evidence quoted in Lai et al. (1991) suggests
that genes in close physical proximity are co-ordinately
regulated. The Ade-D locus of Chinese hamster cells which
encodes phosphoribosyl aminoimidazole carboxylase activity
and maps to chromosome 4 together with the gene for
phosphoribosyl pyrophosphate amidotransferase may be
another example of the coalescence ofrelated genetic inform-
ation and co-ordinate regulation (Barton et al., 1991). In de
novo pyrimidine biosynthesis the first three enzymes also map
in the same region of the chromosome 2p22.p2l and form
the multifunctional CAD protein.
Other possible regulatory mechanisms include the loss or
loss of function of purine responsive elements from the 5'
end of the HPRT gene (Walsh et al., 1990) or of other
regulatory elements such as those which occur in introns 1
and 2 of the human HPRT gene (Reid et al., 1990). In
addition studies of methylation patterns of many genes have
shown that there is an inverse correlation between the level
of methylation and gene activity (Feinburg & Volgstein,
1983; Doerfler, 1983; Riggs & Jones, 1983). In particular
specific sites have been identified within and surrounding the
mouse and human HPRT genes whose methylation status
correlates well with HPRT activity. The region 400bp 3' of
exon 1 is extensively methylated in the inactive X chromo-
some of mouse and humans and completely unmethylated in
the active X chromosome (Yen et al., 1986). A second region
ofdifferential methylation has been identified in the 3' 20 Kb
of the gene which spans exons 3-9. The sites in this region
are completely methylated on the active X and unmethylated
on the inactive X (Lock et al., 1986).
Methylation patterns can also be altered by drug exposure.
Sites in the 5' region of the hamster TK gene became
unmethylated in MNNG induced revertants of TK- cells
(Barr et al., 1986). In addition structural rearrangements,
either spontaneous or drug induced, may bring genes into
proximity with new regulatory elements which act on gene
promotors or may modify the binding of sequence specific
regulatory elements by altering chromatin structure.
Support for the circumvention hypothesis comes from the
work of Kinsella (1991) in studies of drug-resistance in
human embryo fibroblasts of common genetic origin, but
exhibiting phenotypes from normal to aggressively tumouri-
Table I Chromosomal location of genes involved in nucleic acid metabolism
Chromsome
Gene symbol Protein E.C. Number location
adenylate kinase 2
adenylosuccinate synthetase
AMP deaminase 1
AMP deaminase 2
uridine monophosphate kinase
guanylate kinase 1
guanylate kinase 2
carbamoylphosphate synthase
aspartate transcarbamylase
dihydroorotase
adenosine deaminase complexing protein 2
ribonucleotide reductase M2 polypeptide
uridine monophosphate synthetase (OPRT)
phosphoribosyl pyrophosphate amidotransferase
dihydrofolate acid reductase
adenosine deaminase complexing protein 1
5'nucleotidase
uridine phosphorylase
Phosphoribosylpyrophosphate synthetase 1-like I
adenylate kinase 1
adenylate kinase 3
methyl thioadenosine phosphorylase
Phosphoribosylpyrophosphate synthetase 1-like 2
adenosine kinase
ribonucleotide reductase MI polypeptide
phosphoribosylglycinamide formyltransferase
nucleoside phophorylase
5,10-methylenetetrahydrofolate dehydrogenase
5,10-methylenetetrahydrofolate cyclohydrolase
10-formyltetrahydrofolate synthetase
thymidine kinase (mitochondrial)
adenine phosphoribosyl transferase
thymidine kinase (soluble)
UMP phosphohydrolase 2
thymidylate synthase
adenosine deaminase
phosphoribosylaminoimidazole synthetase
phosphoribosylglycinamide synthetase
phosphoribosylglycinamide fornyltransferase
adenylosuccinate lyase
phosphoribo§yl pyrophosphate synthetase 1
phosphoribosyl pyrophosphate synthetase 2
hypoxanthine phosphoribosyl transferase
5,10-methylenetetrahydrofolate dehydrogenase
5,10-methylenetetrahydrofolate cyclohydrolase
10-formyltedrahydrofolate synthetase - like I
Data from HMG 10.5, Cytogenet. Cell Genet., Vol 55, (1990).
AK2
AMPS
AMPD1
AMPD2
UMPK
GUKI
GUK2
CAD
ADACP2
RRM2
UMPS
PPAT
DHFR
ADACP1
NT5
UP
PRPSILI
AKI
AK3
MTAP
PRPS1L2
ADK
RRM1
PFGS
NP
MTHFD
TK1
APRT
TK2
UMPH2
TS
ADA
PAIS
PRGS
PGFT
ADSL
PRPSI
PRPS2
HPRT
MTHFDL1
2.7.4.3
6.3.4.4
3.5.4.17
3.5.4.17
2.7.1.48
2.7.4.8
2.7.4.8.
2.1.3.2.
2.5.2.3.
6.3.4.16
1.17.4.1
2.4.2.10
2.4.2.14
1.5.1.3
3.1.3.5
2.4.2.3
2.7.4.3
2.7.4.3
2.4.2.28
2.7.1.20
1.7.14.1
2.1.2.2
3.4.2.1
1.5.1.5
3.5.4.9
6.3.4.3
2.7.1.21
2.4.2.7
2.7.1.21
3.3.3.5
2.1.1.45
3.5.4.4
6.3.3.1
6.3.4.13
2.1.2.2
4.3.22
2.4.2.17
2.4.2.17
2.4.2.8
3.5.4.9
lp34
lcen-lql2
lpl3-lpl3
lpl3-lpl3
lp32
lq32-q42
lq
2p22-p2l
2p23-qter
2p25-p24
3q13
4pter-q21
5ql1.2-q13.2
6
6q14-q21
7
7p22-qter
9q34.1-q43.2
9p24-p13
9pter-q12
9
10cen-q24
I lpl5.5-pl5.4
14
14q13.1
14q24
16
16q24
16
17q23-q25
18pter-q12
20ql2-q13.1 1
21q22.1
21q22.1
21q22.1
21ql2-qter
Xq2l-q27
Xpter-q21
Xq26
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genic Kinsella et al. (1990). Clonogenic measurements made
in the presence of foetal bovine serum of the intrinsic sen-
sitivities of these cells to the two. cytotoxic drugs MTX and
PALA showed that resistance to both drugs increased with
the progression to morphological transformation, anchorage
independence and growth in nude mice. The difference in
resistance between the immortal and tumourigenic cell lines
was eliminated for both drugs when the experiments were
repeated in dialysed foetal bovine serum, but could be
restored by the addition of hypoxanthine in the case of
resistance to MTX and by the addition of uridine in the case
of resistance to PALA. No evidence for the presence of
amplified DHFR or CAD genes was found in any of these
cell lines which was consistent with their lack of stable
resistance. These observations suggested an important role
for the salvage pathways of purine and pyrimidine biosyn-
thesis in the increased resistance of the more tumourigenic
cell lines.
PALA is a powerful inhibitor of de novo pyrimidine bio-
synthesis whilst MTX, acting on DHFR, inhibits both purine
and pyrimidine biosynthesis. Resistance to both drugs is
commonly but not always (Kinsella & Fox, 1988) due to
amplification, which in the case of resistance to MTX is
DHFR (Schimke et al., 1977) and in the case of resistance to
PALA, the multi-functional CAD gene (Wahl et al., 1979;
Zieg et al., 1983; Meinkoth et al., 1987). The relationship
between gene amplification and tumourigenicity, as assessed
by resistance to MTX and PALA has recently been studied
in mouse fibrosarcoma (Cillo et al., 1989) and in rat liver cell
lines (Otto et al., 1989) exhibiting different degrees of
tumourigenicity. In both studies a striking parallel was
observed between the acquisition of drug resistance due to
gene amplification and increasing tumourigenicity. However,
although gene amplification is usually responsible for the
high frequency of resistance to these drugs following in vitro
selection, amplification of genes mediating drug resistance
has been reported in very few tumours (Wright et al., 1990
and refs therein). The ability of cells to salvage nucleosides
may facilitate amplification by allowing them to survive long
enough for re-replication to occur. However, this is not the
mechanism operating in the study of Kinsella (1991).
These data, although preliminary, support the concept of a
progression-linked change in the key metabolic pathways of
purine and pyrimidine synthesis (Weber, 1983). Not surpris-
ingly, inhibitors of de novo pyrimidine synthesis, such as
PALA, produce a reduction in the intracellular pyrimidine
ribonucleoside (UTP and CTP) and deoxyribonucleoside
(dCTP) triphosphate pools (Plagemann & Behrens, 1976;
Jayaram et al., 1979; Moyer & Handschumacher, 1979;
Moyer et al., 1981; Low & Kufe, 1981). Moreover, the
antiproliferative, cytotoxic and antitumour effects of PALA
can be reversed by the addition of exogenous uridine (John-
son, 1977; Cadman & Benz, 1980; Karle et al., 1980; 1984)
and partially by deoxycytidine (Bhalla & Grant, 1987). What
all these exogenous agents have in common is that they are
either substrates of the salvage pathway enzymes or com-
ponents ofthe de novo pathway distal to the inhibitory block.
Plasma levels ofnucleic acid components
Ifthe circumvention hypothesis is to have any validity for the
clinical situation then we must ask whether purines and
pyrimidines are present in the plasma in sufficient concentra-
tions to compete with achievable plasma concentrations of
drug analogues. Typical of the base analogues used in
therapy is 6MP for which plasma concentrations of 10 M
and -0.1 l.M were achieved immediately after oral and intra-
venous administration respectively, but these levels declined
rapidly over the subsequent 6 h (Zimm et al., 1984). Intra-
venous infusion over 48 h resulted in the maintenance of a
mean plasma concentration of 6.9 tM without host toxicity
(Zimm et al., 1985). In comparison, median values (gM) of
adenosine, inosine and hypoxanthine in plasma from seven
normal individuals at rest were 0.2, 0.6 and 1.3 respectively
(Sinkeler et al., 1986). Plasma hypoxanthine levels were
reported for 16 normal subjects (range 0.2-1.9 1LM, mean
0.561gM), ten untreated leukaemia patients (0.1-1.1 #1M,
mean 0.68gM) and 14 solid tumour patients (0.3-2.6tEM,
mean 0.89tiM) (Wong & Howell, 1984). Thus plasma hypox-
anthine levels varied over a 10-fold range in both normal and
cancer bearing individuals. Plasma adenosine levels in venous
and arterial blood were reported at 0.15 ± 0.03 ylM (n = 15)
respectively (Solleri et al., 1987).
Even higher concentrations of nucleotides are present in
human plasma. It is generally accepted that concentrations of
adenine nucleotides are about 20-30#AM (Gordon, 1985).
Other determinations of adenine nucleotides (ATP + ADP +
AMP) using HPLC have indicated concentrations ranging
from 2-35 jAM (Brankiewicz, personal communication).
High local concentrations of nucleotides and nucleosides
will occur as a result of destruction of tumour cells by
cytotoxic therapy. In addition, extracellular ATP concentra-
tions of >50jLM make erythrocytes semipermeable so that
they release more ATP from their cytoplasm. ATP is also
released from erythrocytes and platelets as a result of trau-
matic shock and during inflammatory reactions, at concen-
trations ranging between 200 ,UM and 1 mM (Gordon, 1985).
Ecto-enzyme cascade generates nucleosides
Nucleosides can be derived from these sources by extracel-
lular nucleotidases present in serum and by ectoenzymes
bound to the external face of the plasma membrane (Figure
3). Thus ecto-ATPase, ecto-ADPase, ecto-ADP kinase and 5'
nucleotidase, present on a variety of cell types (Boyle et al.,
1989; Gutensohn & Rieger, 1986), enable the conversion of
nucleosidetriphosphates (principally ATP, but also GTP,
UTP and CTP at lower rates) to their respective nucleosides.
Plasma nucleotide concentrations will, therefore, represent a
balance between release of nucleotides and their degradation
by extracellular nucleotidases. Thus is would appear that
sufficient concentrations of nucleosides are likely to be avail-
able in vivo to produce significant rescuing effects during
drug-induced cytotoxicity.
Nucleoside transporters control influx andefflux
The uptake of nucleosides resulting from ectoenzyme activ-
ities is mediated by nucleoside transporters (Cass et al.,
1987). Non-concentrative, facilitated diffusion of a broad
range of purine and pyrimidine nucleosides is controlled by
kinetically symmetrical transporters which fall in two classes
with respect to their sensitivity to inhibition by NBMPR,
dilazep and dipyridamole. Sensitive transporters possess high
affinity sites for binding NBMPR which inhibits their activity
in nanomolar amounts. Resistant transporters lack the high
affinity site and are only inhibited by NBMPR at concentra-
tions above 1-10 micromolar. These also possess a broad
specificity but their affinity for some nucleosides may differ
from that of the sensitive transporters. The properties of the
transporter proteins have been reviewed (Plagemann et al.,
1988).
Many cells, including the Morris 3924A rat hepatoma used
in several of the studies by Weber and coworkers, express
both forms of transporter and there is genetic evidence from
mouse S49 (Cohen et al., 1985; Aronow et al., 1985) and
L1210 cells (Belt & Noel, 1988) that the two forms may be
coded by different genes. Other cells appear to express only
one type of transporter, e.g. human erythrocytes and mouse
S49 lymphoma cells are NBMPRS whereas Walker 256 sar-
coma and Novikoff hepatoma cells are NBMPR' (see review
by Paterson et al., 1987).
Active transport of nucleosides has been observed in
epithelial cells of rat (Jakobs & Paterson, 1986) and rabbit
intestine (Jarvis, 1989a) and rat kidney (Le Hir & Dubrach,
1985), murine splenocytes (Plagemann & Woffendin, 1989)
and guinea pig enterocytes (Schwenk et al., 1984). This
system is concentrative and stimulated by sodium ions,
although a component of the rat kidney transporter is also
stimulated by potassium ions. The Km of this type of trans-432 M. FOX et al.
Anthracyciines
Figure 3 Schematic representation of extracellular purine nuc-
leotide metabolism and the pentose phosphate shunt. Also shown
are purine nucleoside and other transporters known to be involv-
ed in drug uptake. es, equilibrative nucleoside transporter
sensitive to NBMPR; ei, equilibrative nucleoside transporter
insensitive to NBMPR; cif, Na+ dependent concentrative trans-
porter; gpl70, efflux transporter encoded by mdr gene or genes;
ct, choline transporter utilised by nitrogen mustard (HN2); aatp,
amino acid transporter proteins utilised by melphalan.
-* indicates drug uptake by passive diffusion. Thick arrows at es
and ei indicate that efflux is more important than influx: Aniti-
metabolite drugs utilise ei, es and cif to varying extents in
different cell lines. Enzymes are in lower case letters; substrates in
upper case. All other abbreviations are specified elsewhere in the
text.
porter is about 20-fold lower than that of facilitated diffusion
transporters, hence at low nucleoside concentrations active
transport predominates whilst at higher concentrations both
types of transporter are active. Sodium-dependent trans-
porters are resistant to NBMPR, dilazep and dipyridamole.
In addition to nucleoside transporters, evidence is accumu-
lating for the occurrence of high affinity nucleobase trans-
porters (see for example, Beck & tJllman, 1989). A recent
overall review of transport systems was provided by Jarvis
(1989b).
Because different tissues vary in the types of nucleoside
transporter they express, the cytotoxicity of nucleoside drugs
can be abrogated to a greater or lesser extent by NBMPR,
dilazep and dipyridamole, a feature that has suggested the
possibility of selective protection of normal tissues by inhib-
itors. Thus Kaplinsky et al. (1986) found that NBMPR
protected normal tissues but not NBMPRr neuroblastoma
cells against tubericidin (7-deazaadenosine). A similar stra-
tegy has been suggested for protecting highly sensitive bone
marrow cells when using tubericidin to treat inhibitor resis-
tant leukaemia (Cass, 1989).
The finding that the cytotoxicity of some nucleoside drugs
can be reduced by transport inhibitors while that of others is
unaffected indicates that different drugs may use various
transporters that have different nucleoside specificities. Prus
et al. (1990) found that transport inhibitors reduced the
cytotoxicity of tubericidin to MOLT 4 and CCRF CEM T
cell lymphoblastic leukaemia cell lines but had no effect on
the cytotoxicity of9-p-D-arabino-furanosylguanine (araG) on
the cells.
A three component pathway mediates reutilisation of
nucleotides
The salvage of nucleosides and nucleobases can thus be
viewed as a three component system comprising the ecto-
enzyme cascade, carrier mediated transport across the plasma
membrane followed by intracellular phosphorylation or phos-
phoribosylation by kinases, e.g. thymidine kinase (TK) or by
phosphoribosyltransferases specific for hypoxanthine and
guanine (HPRT) and adenine (APRT).
The kinetic properties of these components are such as to
generate very effective salvage systems. Extracellular nucleo-
tidases are especially active in endothelial cells, smooth
muscle cells, B lymphoblasts and platelets. The Km value for
pig aorta endothelial cell 5NT was 28ytm (Gordon, 1985)
and the apparent Km for human fibroblasts was 38 nM per
106 cells (Boyle et al., 1989). Apparent Km values of the
lymphoblastoid cell line BHG-83-1 for ATPase and ADPase
were 20JM and 50JAM respectively (Gutensohn & Rieger,
1986).
The Km values of nucleoside transporters for a number of
drug analogues are known to be of the same order of magni-
tude as those for their normal substrates, e.g. adenosine
50-150gM, tubericidin 50-120JM; thymidine 150-250gM,
5-iodo-2-deoxyuridine 90JM. Both 6-thioguanine and 6-mer-
captopurine are efficiently transported by the hypoxanthine
carrier (Km 200-400lAM) whereas 8-azaguanine differs in that
it diffuses through the membrane in its non-ionised form
(pK. 6.6) (Plagemann et al., 1981). 5-Flourouracil is as
efficiently transported by the uracil carrier as is uracil (Km
15 mM) but again only in its non-ionised form (pKa 8.0)
(Wohlhueter et al., 1980).
Phosphorylation or phosphoribosylation involves high
affinity reactions with Km values between 1-1I100M. The Km
values of HPRT for the natural substrates hypoxanthine and
guanine are similar to those for the cytotoxic analogues 6TG
and 6MP (Table II). Some variation is seen between values
for different cell types and between species. Only one study
however (Kong & Parks, 1974) was on purified enzyme,
where the Km was shown to depend on pH.
Several additional lines of evidence indicate the biological
importance of the ecto-enzyme/nucleoside transporter/intra-
cellular phosphorylation route for purine and pyrimidine
salvage and by-pass of drug cytotoxicity.
(1) IMP prevented cytotoxicity caused by MTX in B lym-
phoblastoid cells only if they expressed 5' nucleotidase
(5NT) (Thompson, 1986).
(2) The growth inhibitory effects of high concentrations
(> 50JAM) ofATP, ADP, AMP and adenosine on mouse
3T6 cells were prevented by inhibitors of adenosine
transport, dipyridamole and NBMPR (Weisman et al.,
1988).
(3) Inhibition of de novo purine and pyrimidine synthesis by
acivicin caused cytotoxicity which was synergistically
enhanced by dipyridamole (Weber, 1983; Fisher et al.,
1984).
Synergistic effects ofdipyridamole suggest salvagepathway
involvement
In cancer therapy the mechanism of action of dipyridamole
(DPM, persantin) is primarily through inhibition of nucleo-
side transporters, however in interpreting its synergistic
effects on cancer chemotherapy other mechanisms may also
operate and must be born in mind (Figure 3). Since its
introduction in 1959 DPM has become widely used in the
treatment of cardiovascular disease because it prevents
platelet aggregation, has vasodilatory activity and is non-
toxic (Fitzgerald, 1987). The mechanism of inhibition of
platelet aggregation was thought to involve inhibition of
platelet cyclic AMP phosphodiesterase, however this effect is
rather weak and recently the elevation of plasma adenosine
by blockage of erythrocyte nucleoside transporters has been
proposed (Luthje, 1989). The adenosine then binds to specific
receptors on the platelet surface, causing activation of adeny-
late cyclase and elevation of cyclic AMP levels associated
with inhibition of platelet function. There are also reports
that DPM alters plasma membrane properties (Sowemimo-
Coker et al., 1983; Verscheuruen et al., 1983), potentiates the
inhibition of virus replication (Szebeni et al., 1989) and
induces interferon (Galabov & Mastikova, 1982). Whilst it is
possible that some of these effects are secondary to inhibition
of nucleoside transport, there are clear indications from the
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Table II Km values for various substrates (gM)
Enzyme Cell type Hypoxanthine Guanine Adenine 6TG 6MP Reference
HPRT Mouse sarcoma 5.4 4.0 Van Diggelen et al., (1979)
Chinese hamster V79A 10.0 - 3.0
V79S 10.0 - 12.0 Fox & Hodgkiss (1981)
Human erythrocytes 5.2 12.8 14.0 Kong & Parks (1974)
pH7.0 McDonald & Kelly (1971)
pH7.0 5.0 17.0
Human lymphoblasts 74.0
APRT Human lymphoblasts 33.0 Wood et al. (1973)
cesses. For this reason potentiation by DPM (and probably
NBMPR and dilazap also) should only be taken as a first
indication of the involvement of nucleoside transport in a
process and should be supported by biochemical data.
Since DPM inhibits kinetically symmetrical non-concentra-
tive nucleoside transporters as well as the sodium-dependent
concentrative transporters, it may be expected to inhibit both
influx and efflux of nucleosides. Sometimes these functions
appear to be selectively used by different molecules. Thus
DPM prevents repletion of intracellular nucleotide pools by
blocking influx of normal nucleosides and can also prevent
efflux of fluorodeoxyuridine which leads to elevation of fluo-
rodeoxyuridine monophosphate and the consequent inhibi-
tion of thymidylate synthase as a means of enhancing the
cytotoxicity of 5FU (Grem & Fisher, 1985; Alberts et al.,
1987). This rationale formed the basis of phase I trial of
DPM with 5FU and folinic acid (Budd et al., 1990). A
confounding factor with such treatments in vivo is the
presence in blood of proteins, principally al-acid glyco-
protein, which bind most of the DPM. The variable concen-
tration of al-acid glycoprotein in different individuals may
represent a pharmacogenetic component of drug resistance
(Piafsy & Borga, 1977).
Thymidylate synthase is also inhibited by the quinazolene
antifolate, CB3717, which caused growth inhibition of A549
human lung carcinoma cells that could be overcome by
salvage of exogenous thymidine (Curtin & Harris, 1988). The
cytotoxicity of CB3717 was increased by the presence of
DPM or by the use of dialysed serum to reduce the avail-
ability of exogenous thymidine. DPM was shown to inhibit
influx of TdR by >95% and to inhibit efflux of TdR by
61% and UdR by 89%. The authors argued that these effects
would exacerbate the nucleotide pool imbalance caused by
inhibition of thymidylate synthase and so contribute to
cytotoxicity.
Although we have emphasised the effects of DPM on
nucleoside transport there are also indications that transport
of other molecules may be inhibited (Kessel & Dodd, 1972).
DPM inhibited the uptake of thymidine by sarcoma 180 cells
but also inhibited the efflux of methotrexate (Cabral et al.,
1984; Nelson & Drake, 1984). Sarcoma 180 was also used
with Hela cells to investigate the potentiation of adriamycin
toxicity by DPM (Kusumoto et al., 1988). DPM caused a
2.4-fold decrease in the LDm of adriamycin with 1.4-fold
increase in drug uptake. Using human ovarian carcinoma
2008 cells Howell and coworkers demonstrated synergism
between DPM and cisplatin (Howell et al., 1987), etoposide
(VP-16) (Howell et al., 1989a,b) doxorubicin and vinblastine
(Howell et al., 1989b). In each case DPM increased the
steady state concentrations of the drugs. Only with vinblas-
tine was this accompanied by an increase in the initial influx:
with all drugs the initial rate of efflux was inhibited but not
sufficiently to account for the increased steady state concen-
tration. On this basis it was suggested that DPM was also
affecting other, undefined, mechanisms controlling drug con-
centrations. The possibility that DPM was inhibiting efflux
mediated by the gpl70 MDR1 gene product was discarded
because 2008 cells are relatively sensitive to the drugs used
and hence it was thought unlikely that there would be suffic-
ient gpl70 present for DPM to cause inhibition of efflux at
the magnitude observed. Interaction of DPM with gpl70
needs to be specifically addressed in sensitive and resistant
isogenic cell lines.
There are also numerous other examples, Grem and Fisher
(1985), Nelson and Drake (1984), Fisher et al. (1984), Cabral
et al. (1984), Sobreso et al. (1985) and Chan et al. (1989), of
the sensitisation of cells to the cytotoxic effects of MTX,
PALA and fluorouridine by nucleoside transport inhibitors
and of the rescue from 5-fluorouracil toxicity by uridine.
Resistance to 6-mercaptopurine is multifactorial
The ecto- and cytosolic forms of NT, may be involved in
drug resistance in different ways. The ecto form participates
in the ecto-enzyme/nucleoside transporter system that re-
cycles normal nucleotides which compete with toxic ana-
logues, whereas the cytosolic enzyme may participate in the
dephosphorylation of toxic nucleotides. These alternatives
were offered as explanations (Pieters & Veerman, 1988) of
the observation that children with common-ALL showed a
higher probability of complete remission if the leukaemic
cells were NT- than ifthey were NT+ (Veerman et al., 1985).
The maintenance therapy involved the use of 6-mercapto-
purine and MTX.
Levels of thioguanine nucleotides (TGN), the major cyto-
toxic metabolites of 6MP varied 6.6-fold when measured in
erythrocytes of 120 children with ALL (Lennard & Lilley-
man, 1989). Treatment success was correlated with the attain-
ment of high TGN levels, hence factors such as catabolic
pathways that reduce TGN levels will contribute to poorer
survival. Catabolism occurs via thiopurine methyltransferase
(TPMT) to 6-methyl mercaptopurine, via xanthine oxidase to
6-thiouric acid (Lennard & Lilleyman, 1987) and potentially
through dephosphorylation mediated by cytosolic NT (Pieters
et al., 1987).
As described by Lennard and Lilleyman (1989), 6MP is
subject to first pass detoxification through the intestine and
liver by xanthine oxidase (XO). Although inter-individual
variation in expression of this enzyme in tissues is not
significant, there may be considerable variation in the
amount of XO consumed in food as a consequence of differ-
ences in diet. On the other hand, TPMT shows monogenic
inheritance of two co-dominantly expressed alleles, TPMTL
and TPMTH, controlling low and high levels of activity in
erythrocytes and lymphocytes (Weinshilboum & Sladek,
1980; Van Loon & Weinshilboum, 1982). Individuals
homozygous for L/L occur at a frequency of 1 in 300 and
10% of the population is heterozygous (L/H).
Variations in NT activity are found within blood lympho-
cytes where expression is associated with differentiation and
in leukaemias which appear to reflect blockages in differ-
entiation. Thus 'differentiation-arrested' leukaemias such as T
acute lymphoblastic leukaemia have low NT activity, whereas
'end cell' leukaemias such as common acute lymphoblastic
leukaemia have high NT activity (Gutensohn et al., 1984).
However there is a caveat that these correlations have
generally been made by assaying ecto- rather than cytosolic-
NT activity. Although Boyle et al. (1989) could find no
evidence for separate genes encoding the two forms of NT in
fibroblasts they only assayed for the 'low Km' activity des-
cribed by Spychala et al. (1988). This appears to be a ubiqui-
tous activity which has a preference for AMP and pyrimidine
nucleoside monophosphates with micromolar Km values and
is inhibited by ATP. In contrast a 'high Km' activity prefers
IMP and GMP with millimolar Km values, is stimulated by
ATP other nucleoside triphosphates and glycerate 2,3-biphos-434 M. FOX et al.
phate (Bontemps et al., 1989) and is inhibited by Pi. Thus the
'low Km' enzyme has properties similar to those of ecto-NT
but those of the 'high Km' enzyme appear to be distinct.
Among other tissues the 'high Km' enzyme is found in human
lymphocytes, but it is not known yet which of the soluble
activities show a preference for TGN or how they are exp-
ressed during lymphocyte differentiation.
A further major determinant of the response to MTX and
6MP therapy is the availability of PRPP. Methotrexate
causes inhibition of de novo synthesis and results in increased
PRPP availability. The increased PRPP levels can then be
used for enhanced incorporation of 6MP. Molt 4 (T) Raji (B)
and KM3 (non T non B) human lymphoblastoid cells have
been compared with respect to the activities ofpurine de novo
(PDNS) and salvage pathways. Molt 4 showed high activity
of both pathways, Raji had low PDNS and an active salvage
whereas both pathways were moderately active in KM3. The
time course of elevation of PRPP levels was measured after
MTX exposure (0.02ytM and 0.2ilM) in all three lines and
the amount of hypoxanthine and 6MP incorporated was
shown to be directly correlated at each time point with the
PRPP level. The absolute amount of 6MP incorporated cor-
related with the activity of the purine salvage pathway.
Overall the data indicate that Raji and Molt 4 cells will be
more sensitive to the cytotoxic effect of MTX plus 6MP than
KM3 cells (Bokkerink et al., 1988a,b).
Perspectives
In this review we have cited evidence in support of the
hypothesis that salvage of nucleotides involving an ecto-
enzyme cascade, nucleoside transport and endogenous phos-
phorylation is a significant mechanism in resistance to a
whole variety of antitumour agents. The underlying mechan-
ism is the circumvention of the inhibition of key enzymes of
de novo purine or pyrimidine synthesis as proposed by Nat-
sumeda et al. (1989) on biochemical grounds. Our own
quoted data (Kinsella, 1991) provide biological support for
the idea and in this review we have emphasised the contribu-
tion of ecto-enzymes to the process. There is ample evidence
that nucleosides are present in serum at concentrations
sufficient to fulfill a salvage function and may be augmented
locally from the nucleic acids of dying cells in a tumour. The
ecto-enzymes involved in the nucleotide cascade are highly
active at the observed physiological concentrations of nucleo-
tides. As the genes involved in salvage and de novo synthesis
are cloned into expression vectors, their transfection into
non-expressing recipient cells offers a powerful means of
testing the details and implications of the hypothesis. Salvage
pathways appear to be particularly important in leukocytes,
where deficiencies of adenosine deaminase, purine nucleoside
phosphorylase and 5' nucleotidase appear to be associated
with suppression of immunological function. Similar deficien-
cies occur in some leukaemias and their investigation and
correction by genetic engineering promises to illuminate our
understanding of the role of salvage not only in drug resis-
tance but also in the wider aspects of leucocyte differentiation
and leukaemogenesis.
This work was supported by Grants from the Cancer Research
Campaign.
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